SCRIP
CITELINE COMMERCIAL

12 Jun 2022 | **News**

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast version of Five Must-Know Things: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS' targeted oncology acquisition; a snapshot of the multiple sclerosis market; and a look at Aduhelm one year later.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip*'s global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 10 June 2022, including: paradigm-shifting breast cancer and KRAS inhibitor results at ASCO; BMS' targeted oncology acquisition; a snapshot of the MS market; and a look at Aduhelm one year later.

This and all our other podcasts are available on the Pharma Intelligence channel on *Apple Podcasts*, *Google Podcasts*, *SoundCloud*, *TuneIn* and *Spotify Podcasts*, and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "*ASCO: AstraZeneca's Enhertu Is Poised To Change The Breast Cancer Paradigm*" - Scrip, 5 Jun, 2022.)

(Also see "*Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field*" - Scrip, 6 Jun, 2022.)

(Also see "*BMS Hopes Turning Point Buyout Will Fare Better Than Roche's Ignyta Acquisition*" - Scrip, 3 Jun, 2022.)

(Also see "*MS Market Snapshot: New Options Confront Commercial Reality Of A Crowded Space*" -

© Citeline 2024. All rights reserved.

Scrip, 3 Jun, 2022.)

(Also see "*How Biogen's Aduhelm Bet Became A Commercial Bust*" - Scrip, 6 Jun, 2022.)

Click here to explore this interactive content online

© Citeline 2024. All rights reserved.